Cargando…

ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor

PURPOSE: In this study, anaplastic lymphoma kinase (ALK) mutation and amplification, ALK protein expression, loss of the nuclear alpha thalassemia/mental retardation syndrome X-linked (ATRX) protein, and telomerase reverse transcriptase (TERT) protein expressionwere studied to investigate potential...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Ji Won, Park, Sung Hye, Kang, Hyoung Jin, Park, Kyung Duk, Shin, Hee Young, Ahn, Hyo Seop
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912141/ https://www.ncbi.nlm.nih.gov/pubmed/28546523 http://dx.doi.org/10.4143/crt.2016.577

Ejemplares similares

Retrospective Analysis of Peripheral Blood Stem Cell Transplantation for the Treatment of High-Risk Neuroblastoma
por: Kim, Eun Kyung, et al.
Publicado: (2007)

Treatment outcomes in children with Burkitt lymphoma and L3 acute lymphoblastic leukemia treated using the lymphoma malignancy B protocol at a single institution
por: Park, Eun Sil, et al.
Publicado: (2011)

Chronic graft versus host disease with small bowel obstruction after unrelated hematopoietic stem cell transplantation in a patient with acute myeloid leukemia
por: Yoon, Ju Young, et al.
Publicado: (2012)

Successful Treatment of Primary Central Nervous System Lymphoma without Irradiation in Children: Single Center Experience
por: Yoon, Jong Hyung, et al.
Publicado: (2012)

Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment
por: Hong, Kyung Taek, et al.
Publicado: (2012)

Hemophagocytic lymphohistiocytosis diagnosed by brain biopsy
por: Ju, Hee Young, et al.
Publicado: (2015)

Respiratory Viral Infections after Hematopoietic Stem Cell Transplantation in Children
por: Choi, Jae Hong, et al.
Publicado: (2013)

ARID1B alterations identify aggressive tumors in neuroblastoma
por: Lee, Soo Hyun, et al.
Publicado: (2017)

Clinical Characteristics of Pediatric Thalassemia in Korea: A Single Institute Experience
por: Hong, Che Ry, et al.
Publicado: (2013)

Double umbilical cord blood transplantation for children and adolescents
por: Kang, Hyoung Jin, et al.
Publicado: (2010)

Successful Salvage Unrelated Umbilical Cord Blood Transplantation with Two Units After Engraftment Failure with Single Unit in Severe Aplastic Anemia
por: Lee, Ji Won, et al.
Publicado: (2009)

Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients
por: Kim, Bora, et al.
Publicado: (2017)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Myeloablative treatment supported by autologous stem cell infusion with neuroblastoma.
por: Ryu, Kyung Ha, et al.
Publicado: (2003)

Improved Survival in Patients with Recurrent Wilms Tumor: the Experience of the Seoul National University Children's Hospital
por: Park, Eun Sil, et al.
Publicado: (2006)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

Pharmacogenetic Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia: A Possible Association between Survival Rate and ITPA Polymorphism
por: Kim, Hyery, et al.
Publicado: (2012)

Targeted busulfan and fludarabine-based conditioning for bone marrow transplantation in chronic granulomatous disease
por: Ju, Hee Young, et al.
Publicado: (2016)

ALK in Neuroblastoma: Biological and Therapeutic Implications
por: Trigg, Ricky M., et al.
Publicado: (2018)

Improvement of Induction Remission Rate by Modifying the Dose of Idarubicin for Relapsed Childhood Acute Lymphoblastic Leukemia
por: Yoon, Jong Hyung, et al.
Publicado: (2009)

The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness
por: Mus, Liselot M., et al.
Publicado: (2020)

Growth after Hematopoietic Stem Cell Transplantation in Children with Acute Myeloid Leukemia
por: Chung, Seung Joon, et al.
Publicado: (2013)

Extra-cranial Malignant Rhabdoid Tumor in Children: A Single Institute Experience
por: Hong, Che Ry, et al.
Publicado: (2015)

Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study
por: Koh, Kyung-Nam, et al.
Publicado: (2017)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

MYCN and mutationally activated ALK synergise in neuroblastoma
Publicado: (2012)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

Loss of ALK hotspot mutations in relapsed neuroblastoma
por: Allinson, Lisa M., et al.
Publicado: (2022)

Genomic ALK alterations in primary and relapsed neuroblastoma
por: Rosswog, Carolina, et al.
Publicado: (2023)

Association of systolic blood pressure drop with intravenous administration of itraconazole in children with hemato-oncologic disease
por: Lee, Hyeong Jin, et al.
Publicado: (2015)

The impact of HLA matching on unrelated donor hematopoietic stem cell transplantation in Korean children
por: Park, Meerim, et al.
Publicado: (2011)

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
por: Borenäs, Marcus, et al.
Publicado: (2021)

Activating mutations in ALK provide a therapeutic target in neuroblastoma
por: George, Rani E., et al.
Publicado: (2008)

The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status
por: Trigg, Ricky M., et al.
Publicado: (2019)

Metastatic Burden Defines Clinically and Biologically Distinct Subgroups of Stage 4 High-Risk Neuroblastoma
por: Seo, Eun Seop, et al.
Publicado: (2020)

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
por: Pacenta, Holly L, et al.
Publicado: (2018)

5′ ALK Amplification in Neuroblastoma: A Case Report
por: Akhavanfard, Sara, et al.
Publicado: (2021)

Identification of ALK Mutation in Neuroblastoma on the Point of Molecular Heterogeneity
por: Aktaş, Tekincan Çağrı, et al.
Publicado: (2023)

Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer
por: Ji, Jun Ho, et al.
Publicado: (2015)

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gk7u5itv6lvk7rhe1lfe562228